Results 91 to 100 of about 24,145,261 (292)

Clinicopathological characteristics of diffuse large B-cell lymphoma.

, 2014
Clinicopathological characteristics of diffuse large B-cell lymphoma.
Paloma Martín (144198), Linah Kilany (571307), Carmen Bellas (571304), Yolanda Vicente (571306), Victor Abraira (148934), Mariano Provencio (255839), Diego García (571305), Belen Navarro (571308)   +7 more
core   +1 more source

MicroRNAs in diffuse large B-cell lymphoma

Oncology Letters, 2015
The aberrant expression of microRNAs (miRs) has a significant impact on the biological characteristics of lymphocytes, and is important in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). It has been demonstrated, using miR profiling and detecting distinct miR signatures, that certain miRs may accurately distinguish different subtypes and ...
Huiyun, Ni, Rong, Tong, Linqing, Zou, Guoqi, Song, William C, Cho   +4 more
openaire   +3 more sources

A Case of a Rapidly Progressive Small Bowel Lymphoma with High Ki-67 Expression

The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017
Primary intestinal lymphoma is a rare disease. It accounts for approximately 1∼4% of gastrointestinal malignancy. Extranodal lymphoma of the intestine mainly arises from B cells.
Jiyeon Yoo, Hee Jun Kang, Hyungkeun Kim, Sujeong Han, Seung Hyun Oh, Sung Hoon Jung, Jung Hwan Oh, Eun Jung Jeon   +7 more
doaj   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

The Treatment of Diffuse Large B-Cell Lymphoma (Triple Expression) Involving the Breast, Spleen, and Bone in a Male Patient with Viral Hepatitis B: A Rare Case Report

, 2023
Weiling Zhou,1 Qian Gao,1 Lianjing Wang,2 Weijing Li,2 Cuiying He,2 Yanting Li,3 Lei Feng,1 Wei Liu,2 Lihong Liu,2 Yuan Wang1 1Department of Endocrine and Metabolic Diseases, The Fourth Hospital of Hebei Medical University, Shijiazhuang, HeBei Province ...
Gao Q, Li W, He C, Li Y, Feng L, Liu L, Zhou W, Wang Y, Wang L, Liu W   +9 more
core  

Peripheral Blood DNA Methylation Changes Precede Lymphoma Diagnosis in Primary Sjögren's Disease

Arthritis &Rheumatology, EarlyView.
Objective Primary Sjögren's disease (SjD) is a systemic autoimmune disease associated with an increased risk of lymphoma. The molecular mechanisms underlying lymphomagenesis remain poorly understood, and sensitive biomarkers for early identification of patients at high risk of developing lymphoma are lacking.
Hanna Lidberg, Cecilia Fugmann, Juliana Imgenberg‐Kreuz   +2 more
wiley   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Haematologica, 2017
Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol
Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim   +11 more
doaj   +1 more source

Diagnosis and treatment of diffuse large B-cell lymphoma

Swiss Medical Weekly, 2012
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituximab typically in combination with cyclophosphamide ...
Mey, U, Hitz, F, Lohri, A, Pederiva, S, Taverna, C, Tzankov, A, Meier, O, Yeow, K, Renner, C   +8 more
openaire   +3 more sources

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience

, 2019
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life ...
Castellino A., Zinzani P. L., Visco C., Marasca R., Rigacci L., Visco, Carlo, Castellino C., Castellino, Claudia, Stefoni, Vittorio, Argnani, Lisa, Rusconi C., Tecchio, Cristina, Zinzani, Pier Luigi, Tani, Monica, Tani M., Monaco F., Monaco, Federico, Devizzi L., Gaudio F., Gaudio, Francesco, Rigacci, Luigi, Tecchio C., Romano A., Marangon, Miriam, Castellino, Alessia, Marangon M., Marasca, Roberto, Rusconi, Chiara, Devizzi, Liliana, Cox M. C., Argnani L., Cox, Maria Christina, Romano, Alessandra, Stefoni V.   +33 more
core   +1 more source